subcutaneous ALX-0061: Phase Ib started

Ablynx began an open-label Phase Ib trial to compare single doses of 50, 150 and 300 mg subcutaneous ALX-0061 vs. single doses of 50 and 300 mg IV ALX-0061 in about 70 healthy volunteers. Ablynx plans to start Phase II testing of the subcutaneous formulation in rheumatoid arthritis and systemic lupus erythematosus (SLE) next year. An IV formulation of ALX-0061 has completed a Phase I/II trial to treat moderate to severe active RA. Ablynx and AbbVie partnered to develop ALX-0061 to treat inflammatory diseases last September (see BioCentury, Sept. 30, 2013). ...